Source:http://linkedlifedata.com/resource/pubmed/id/19614835
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2009-7-20
|
| pubmed:abstractText |
The objectives of this study were to determine pharmacokinetics of intravenous (i.v.) ceftiofur in foals, to compare ultra-high performance liquid chromatography tandem mass spectometry (UPLC-MS/MS) and microbiologic assay for the measurement of ceftiofur concentrations, and to determine the minimum inhibitory concentration (MIC) of ceftiofur against common equine bacterial pathogens. In a cross-over design, ceftiofur sodium was administered i.v. to six foals (1-2 days-of-age and 4-5 weeks-of-age) at dosages of 5 and 10 mg/kg. Subsequently, five doses of ceftiofur were administered i.v. to six additional foals between 1 and 5 days of age at a dose of 5 mg/kg q 12 h. Concentrations of desfuroylceftiofur acetamide (DCA), the acetamide derivative of ceftiofur and desfuroylceftiofur-related metabolites were measured in plasma, synovial fluid, urine, and CSF by use of UPLC-MS/MS. A microbiologic assay was used to measure ceftiofur activity for a subset of plasma samples. Following i.v. administration of ceftiofur at a dose of 5 mg/kg to 1-2 day-old foals, DCA had a t(1/2) of 7.8 +/- 0.1 h, a body clearance of 74.4 +/- 8.4 mL/h/kg, and an apparent volume of distribution of 0.83 +/- 0.09 L/kg. After multiple i.v. doses at 5 mg/kg, DCA concentrations in CSF were significantly lower than concurrent plasma concentrations. Ceftiofur activity using a microbiologic assay significantly underestimated plasma concentrations of DCA. The MIC of ceftiofur required to inhibit growth of 90% of isolates of Escherichia coli, Pasteurella spp, Klebsiella spp, and beta-hemolytic streptococci was <0.5 microg/mL. Intravenous administration of ceftiofur sodium at the rate of 5 mg/kg every 12 h would provide sufficient coverage for the treatment of susceptible bacterial isolates.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1365-2885
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
32
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
309-16
|
| pubmed:meshHeading |
pubmed-meshheading:19614835-Animals,
pubmed-meshheading:19614835-Animals, Suckling,
pubmed-meshheading:19614835-Anti-Bacterial Agents,
pubmed-meshheading:19614835-Cephalosporins,
pubmed-meshheading:19614835-Chromatography, Liquid,
pubmed-meshheading:19614835-Cross-Over Studies,
pubmed-meshheading:19614835-Escherichia coli,
pubmed-meshheading:19614835-Female,
pubmed-meshheading:19614835-Gram-Negative Bacteria,
pubmed-meshheading:19614835-Gram-Positive Cocci,
pubmed-meshheading:19614835-Horses,
pubmed-meshheading:19614835-Infusions, Intravenous,
pubmed-meshheading:19614835-Klebsiella,
pubmed-meshheading:19614835-Linear Models,
pubmed-meshheading:19614835-Male,
pubmed-meshheading:19614835-Pasteurella,
pubmed-meshheading:19614835-Serum Bactericidal Test,
pubmed-meshheading:19614835-Streptococcus agalactiae
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Pharmacokinetics of intravenous ceftiofur sodium and concentration in body fluids of foals.
|
| pubmed:affiliation |
Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA.
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|